We estimated costs of managing different forms of tuberculosis (TB) across Canada by conducting a retrospective chart review and cost assessment of patients treated for TB infection, drug-susceptible TB (DS TB), isoniazid-resistant TB, or multidrug-resistant TB (MDR TB) at 3 treatment centers. We included 90 patients each with TB infection and DS TB, 71 with isoniazid-resistant TB, and 62 with MDR TB. Median per-patient costs for TB infection (in 2020 Canadian dollars) were $804 (interquartile range [IQR] $587–$1,205), for DS TB $12,148 (IQR $4,388–$24,842), for isoniazid-resistant TB $19,319 (IQR $7,117–$41,318), and for MDR TB $119,014 (IQR $80,642–$164,015). Compared with costs for managing DS TB, costs were 11.1 (95% CI 9.1–14.3) times lower for TB infection, 1.7 (95% CI 1.3–2.1) times higher for isoniazid-resistant TB, and 8.1 (95% CI 6.1–10.6) times higher for MDR TB. Broadened TB infection treatment could avert high costs associated with managing TB disease.

我们通过对接受结核感染、药物敏感结核病 (DS TB)、异烟肼耐药结核病或耐多药结核病治疗的患者进行回顾性图表审查和成本评估，估算了加拿大各地管理不同形式结核病 (TB) 的成本（耐多药结核病）在 3 个治疗中心。我们纳入了 90 名结核感染和 DS TB 患者，71 名异烟肼耐药结核病患者和 62 名耐多药结核病患者。结核病感染的每位患者成本中位数（以 2020 年加元计算）为 804 美元（四分位间距 [IQR] 587-1,205 美元），DS TB 为 12,148 美元（IQR 4,388-24,842 美元），异烟肼耐药结核病为 19,319 美元（IQR 7,117-41,318 美元） , 以及耐多药结核病 119,014 美元（IQR 80,642-164,015 美元）。与管理 DS TB 的成本相比，TB 感染的成本低 11.1 (95% CI 9.1–14.3) 倍，异烟肼耐药 TB 的成本高 1.7 (95% CI 1.3–2.1) 倍，8.1 (95% CI 6.1– 10. 6) 耐多药结核病高出一倍。扩大结核病感染治疗范围可以避免与管理结核病相关的高额费用。